Monoclonal antibodies which react with herpes simplex virus type 1 (HSV-1) glycoproteins, but do not neutralize infectivity, were prepared. The protein to which each monoclonal antibody was directed was determined by various techniques including their reaction with polypeptides from glycoprotein-deficient mutants after protein blotting, and also tests using passive haemagglutination. Monoctonal antibodies A7 and ~C3 were directed against a type-specific determinant on gC and a type-common determinant on gB respectively. In addition, A7 reacted only with the HFEM strain of HSV-1 and did not react with any of the 20 low-passage human isolates also tested. The monoclonal antibodies were used in immunoadsorption chromatography to purify individual glycoproteins from detergent extracts of HSV-l-infected cells. The ability of the monoclonal antibodies or purified glycoproteins to protect mice against a lethal encephalitis induced by intracerebral inoculation of HSV-1 was investigated. Passive immunization was not very effective; however, purified gC or a mixture of gB and its precursor pgB induced good levels of neutralizing antibody which persisted for at least 9 weeks and mice survived virus challenge.
INTRODUCTION
Herpes simplex virus type 1 (HSV-1) contains four major glycoproteins (Spear, 1976; Norrild, 1980) designated in order of decreasing mol. wt. gC, gB, gE and gD. A precursor to gB (pgB), previously referred to as gA, is also found in infected cells and virus particles (Eberle & Courtney, 1980; Pereira et al., 1981) . Antibodies to these glycoproteins are formed after virus infection in humans (Gilman et al., 1981 : Zweerink & Corey, 1982 A rvin et al., 1983; Eberle & Mou, 1983) . and antisera (Honess & Watson, 1974 , Powell et al., 1974 Norrild, 1980) or monoclonal antibodies (Showalter et al., 1981 : Pereira et al., 1982 : Rector et al., 1982 Cranage et al., 1983) to individual glycoproteins will neutralize virus infectivity in vitro.
Monoclonal antibodies directed against virus glycoproteins have successfully been used to protect mice passively against HSV infection (Dix et al., 1981 ; Rector et al., 1982; Balachandran et al., 1982b; Sethi, 1983) . More recently the purification of gD by immunoadsorption chromatography using a monoclonal antibody and its use as an experimental vaccine in mice have been described (Eisenberg et al., 1982; Long et al., 1984) while Schrier et al. (1983) have purified a glycoprotein, presumptively gC, which also confers protection to mice. In the present study we have investigated the use of purified gB or gC as protective antigens. Monoclonal antibodies to these HSV-1 glycoproteins, including one to gC that is specific for the HFEM strain, have been prepared and characterized. The monoclonal antibodies were not very effective for the passive immunization of mice. However gB or gC, purified by immunoadsorption chromatography, induced neutralizing antibody and mice were protected against HSV-I infection. treated with 0.005 % (w/v) tannic acid in PBS pH 6.4 for 20 min at 37 °C. The cells were washed and resuspended at a concentration of 20/0 (v/v) in an optimal dilution of antigen in PBS pH 6-4 which had been determined previously by a chequerboard titration. Routinely about 10 ~g/ml of affinity chromatography-purified protein or 100 ~ag/ml of purified virus, or a detergent extract of purified virus, was used. After 30 min at 37 °C the cells were washed and stored at a concentration of 0-5°,0 (v/v) in PBS pH 7-2 containing 1% (v/v) heat-inacti'cated rabbit serum.
The PHA was performed by mixing 75 lal of antiserum, diluted in fourfold steps in PBS pH 7.2 containing 1 °' o (v/v) heat-inactivated turkey serum, with 25 ~al of antigen-sensitized cells in V-wells of microtitre plates. The plates were shaken and the antiserum dilution at which 50°,0 haemagglutination occurred (PHA~0) was recorded after 1 to3h.
In the constant antigen method for the assay of antigen by blocking, wells containing various dilutions of antiserum were each incubated with 5 ~tl of undiluted antigen. When testing the strain specificity of the monoclonal antibodies, 25 ~l of supernatant fluid from BHK cells was taken 5 days after infection, when a clear c.p.e, had developed, and used as antigen. After 1-5 h the residual antibody titre was determined by PHA. In the constant antibody method each well contained 8 PHAs,~ units of antibody and the dilution of antigen that would abolish this activity was determined.
Direct immunoprecipitation. Detergent cell extracts labelled with [~~C]glucosamine were incubated with antiserum for 24 h at 4 '~C. The precipitates were centrifuged at 1500 g for 15 rain through a 7% (w/v) sucrose cushion. The pellets were washed with PBS and resuspended in gel disruption buffer.
Immunoad~'orption chromatography. Monoclonal antibodies A7 and ~C3 were used to purify their respective antigens by affinity chromatography and the antiserum to the oligomeric form of gB was used to purify gB. Immunoglobulins were precipitated from antiserum or ascitic fluid with 50% saturated ammonium sulphate and coupled to Sepharose CL-4B (Pharmacia) activated with sodium metaperiodate (Raybould & Chantler, 1979) or to CNBr-activated Sepharose 4B (Pharmacia) following the manufacturer's instructions. Proteins were used at 5 mg/ml of Sepharose and uptake was >80o./o. Columns consisting of 2 to 5 ml, i.e. 0.5 to 1.5 g, of IgG-linked Sepharose, over a 5 to 20 ml layer of Sephadex G-25 (Pharmacia), were routinely used. The Sephadex layer (Raybould & Chantler, 1980) enabled the eluted antigen to be separated from the eluting agent. Detergent extracts of infected cells were applied and the column extensively washed with 0.1 °, o (v/v) NP40 in PBS and finally with PBS. The bound material was then eluted with 3 M-NaSCN. The fractions containing the protein peak, which eluted before the NaSCN, were pooled and either used directly or dialysed against H20 and freeze-dried. Protein yields were determined using the method of Lowry et al. (1951) .
Polyaco'lamide gel electrophoresis. Samples were analysed on 9°o SDS-polyacrylamide slab gels cross-linked with N,N'-diatlyltartardiamide, using a discontinous buffer system (Maizel, 1971) . After electropboresis gels were either used for protein blotting or subjected to fluorography (Dimmock & Watson, 1969) .
Protein blotting. Polypeptides were transferred from unfixed gels to 0.2 or 0-45 ~tm nitrocellulose sheets (Schleicher & Schiill) at 60 V for 15 h (Towbin et al., 1979 : Burnette, 1981 ) using a Bio-Rad Trans-Blot apparatus.
The nitrocellulose sheet was then incubated with blocking buffer which contained 1 ° o (w/v) bovine serum albumin and 5 % (v/v) calf serum in PBS for 2 h at room temperature. After washing with 0.1% (v/v) N P40 in PBS, the sheet was incubated with antiserum at a dilution of 1/100 to 1/1000 in blocking buffer containing 0-1 °, o (v/v) NP40 for 2 h. The sheet was again washed and peroxidase-conjugated rabbit anti-mouse IgG or swine anti-rabbit IgG (Dako) added at a dilution of 1/500 in blocking buffer containing 0-1 ° o (v/v) NP40. After a further 2 h the sheet was again washed and substrate comprising 0-15°o (w/v) Hanker-Yates reagent (Polysciences, Northampton, U.K), a mixture ofp-phenylenediamine and pyrocatechol, and 0. Mwe protection experiments. Adult BALB/c mice which had been passively or actively immunized were challenged by intracerebral inoculation with a dose of crude HSV-I estimated to contain about 30 LDs~, and monitored for 2 weeks. The ability of this dose of virus to kill the mice was verified at the same time as the mice were challenged. Passive immunization was performed by intraperitoneal injection of 0.1 ml of antibody 2 h before challenge and 0. I m124 h after challenge. Active immunization was performed by giving mice two or three footpad injections of about 10 ~ag of antigen in Freund's incomplete adjuvant at intervals of 2 months. Levels of neutralizing antibody were determined at various times after the final boost and the mice received a challenge dose.
RESULTS

Preparation and initial characterization of monoclonal atttibodies
Two fusions produced 36 hybridoma cultures. The supernatant fluids from 13 of these reacted in ELISA with a detergent extract of HSV-l-infected cells and five also reacted strongly with a detergent extract of purified HSV-I. Two hybridoma cultures, designated A7 and c~C3, which 0'12 ĩ also reacted in PHA were selected for further study. These were cloned and used to produce ascitic fluid in which the antibody titre against purified virus, as determined by ELISA and PHA, was 100-to 1000-fold higher than that obtained using the hybridoma supernatant fluids. Neither antibody neutralized infectivity even when a 24 h test was used and complement was added. Monoclonal antibodies A7 and c~C3 were determined to be ]gG 2b and IgG 2a by immunodiffusion using class-and subclass-specific antisera. The determinants recognized by the monoclonal antibodies A7 and ~C3 were found by PHA to be type-specific and type-common respectively (Table 1 ). The strain specificity of A7 was investigated by PHA using a constant antigen blocking test. Monoclonal antibody A7 gave a log10 titre of 7.0 in both the absence of blocking antigen or in the presence of 20 low-passage human HSV-1 isolates. Only the HFEM strain, to which this antibody had originally been prepared, was able to block the reaction and reduced the antibody titre of A7 to 5.2.
Immunoadsorption chromatography
The two monoclonal antibodies were each linked to Sepharose 4B and used in affinity chromatography to purify their respective antigens from detergent extracts of HSV-l-infected cells. This is illustrated in detail for a monoclonal antibody A7 column using a [3SS]methioninelabelled cell extract ( Fig. 1 and 2a) . The use of a layer of Sephadex G-25 underneath the antibody-linked Sepharose enabled the rapid separation of the eluting antigen from the N a S C N ( Fig. 1) and thus reduced the likelihood of any antigen denaturation. The flow-through fraction which did not bind to the column was depleted of a single polypeptide, which migrated at about the position expected for gC, when compared to the original extract (Fig. 2a, lanes 3 and 4) . This polypeptide was detected in the fraction eluted from the column with N a S C N (Fig. 2a, lane 5) . The monoclonal antibodies are directed against different high mol.wt, virus glycoproteins (see next section). The purified A7 and c~C3 antigens were judged to be relatively free of other virus proteins, particularly glycoproteins, by fluorography (Fig. 2a , lane 5) and PHA (Table 1 ).
In addition immunoperoxidase staining of protein blots, using an HSV-1 general antiserum, revealed one predominant band in the purified A7 antigen (Fig. 2b , lane 1) which was clearly different to the ~C3 antigen (Fig. 2b, lane 2) . The lower mol.wt, component detected in the purified ~C3 antigen (Fig. 2b , lane 2) probably represents a precursor or degradation product. Most significantly, neither antigen appeared to contain additional proteins of lower mol.wt, in the positions expected for gD or gE. The yields from 2 ml immunoadsorbent columns prepared using CNBr-activated Sepharose were estimated. Using A7, about 700 ~tg of protein could be extracted from a detergent extract of 1>2 x 108 HSV-l-infected Chang cells. If larger volumes of extract were used, significant amounts of A7 antigen were found in the flow-through fraction. The yield from an ctC3 column was about 300 p.g from an extract of /> 1 x 108 cells.
Identification of proteins recognized b.v the monoclonal antibodies Passive haemagglutination assay
The antigen to which each monoclonal antibody was directed was initially identified by investigating their reaction with red blood cells coated with various virus antigens including those purified by immunoadsorption chromatography (Table l) . Both A7 and ~C3 reacted with purified virus, or a detergent extract of purified virus, suggesting that surface glycoproteins in the virus envelope were involved. The antigens purified using the monoclonal antibodies were recognized by an antiserum to gB+gC but not an antiserum to gD. However, the antigens appear to be different because the purified A7 antigen does not react with monoclonal antibody ~C3 and, conversely, the purified c~C3 antigen does not react with monoclonal antibody A7.
The antiserum to the oligomeric form of gB reacted with the purified 7C3 antigen but not the A7 antigen. Also purified gB reacted with the monoclonal antibody c¢C3 but not A7. This would suggest that monoclonal antibody 7C3 is directed against gB and, because the monoclonal antibodies recognize different high mol.wt, glycoproteins (either gB or gC), it can be deduced that A7 is directed against gC. The results of studies in which the reaction between antigencoated cells and antibody was blocked with purified antigens is consistent with this conclusion (Table 2 ). The reactivity of the monoclonal antibody ~C3, but not A7, could be blocked by purified gB and the antibody to the oligomeric form ofgB could be blocked by the purified ~C3 antigen but not the A7 antigen.
Immunoprecipitation
In initial experiments the 35S-labelled polypeptide which eluted from an A7 immunoadsorbent column, which migrated in the high mol.wt, glycoprotein region, was tentatively identified as gC (Fig. 2) . Furthermore PHA had suggested that monoclonal antibody A7 was directed against gC, and c~C3 to gB. Gel electrophoresis of [laC]glucosamine-labelled extracts of cells which had been infected with the gB-mutant tsB5 at 39 °C (Fig. 3, lane 3) or the gC-mutant A1056 (Fig. 3 , lanes 5 and 6) was used to identify the individual virus glycoproteins and to confirm the identity of the A7 antigen (Fig. 3) , Monoclonal antibody A7 (lane 7), or a rabbit antiserum to the A7 antigen (lane 4), immunoprecipitated a glycoprotein which comigrated with gC. The antigen eluted from an A7 immunoadsorbent column also had the properties of gC (lane
8).
Protein blotting
The reaction of the monoclonal antibodies with infected cell extracts that had been transferred to nitrocellulose was investigated (Fig. 4) . Initial studies showed that A7 recognized a high mol.wt, polypeptide which corresponded to the major antigen detected by an antiserum to purified virus (Fig. 4a, lanes 2 and 3) . In contrast, monoclonal antibody c~C3 reacted weakly with a component(s) of slightly lower molecular weight (Fig. 4a, lane 1) .
Extracts from cells infected with tsB5 at 34 °C ( Fig. 4b to d, lanes 1 ), tsB5 at 39 °C (gB-) (lanes 2) or 13 v B4 (gC-) (lanes 3) were also transferred to nitrocellulose and their reaction with antibody was investigated. The extracts were labelled with [l~C]glucosamine and thus it was possible to identify the individual virus glycoproteins by autoradiography (Fig. 4d) . The monoclonal antibody A7 (Fig. 4b) detected a polypeptide which comigrated with [14C]glucosamine-labelled gC only in those cell extracts which contained gC (lane 1 and 2) but not in the extract which lacked gC (lane 3). The reaction of a hyperimmune rabbit antiserum to the c~C3 antigen with the extracts from cells infected with the glycoprotein-deficient mutants was also investigated (Fig. 4c) . This antiserum was used because the monoclonal antibody itself reacted poorly in this technique. A polypeptide which comigrated with [L~C]glucosamine-labelled pgB, the precursor to gB, was detected in all cases (lanes 1, 2 and 3). A polypeptide which comigrated with gB was otlly detected in those extracts which contained gB (lanes I and 3) but not in the extract which lacked gB (lane 2). A minor component of higher mol.wt, was also detected: however, its significance is unclear. In some experiments a minor band labelled with [~ ~C]glucosamine was detected at this position. The rabbit antiserum prepared to the oligomeric form of gB reacted in a way similar to that of the rabbit antiserum to the c~C3 antigen shown in Fig. 4(c) (not shown): however, it did not recognize the higher mol.wt, component.
Protection e.vperiments in mice
HSV-I strain H F E M did not affect mice after intraperitoneal or footpad inoculation at a dose of up to 2 x 107 p.f.u./mouse. However, encephalitis and death followed intracerebral inoculation with an LDs0 of about 500 p.f.u./mouse. Death occurred within 3 to 8 days when a dose of 30 LDs0/mouse was used. Virus titres of about l0 s p.f.u./g were found in the brain at the time of death. A challenge dose of 30 LDs0 was used in the protection experiments. Table 3 . Protection ol" mice against HS V-1 using monoclonal antibodies Antiserum* Target antigen Survivors/total Mean time of death (days) +_ S.E.M. A7 gC 0/6 2.3 + 0.2 aC3 gB 0/6 2"0 + 0.0 A7 + c~C3 gC + gB 0/6 3.8 + 0.5 P < 0.02:~ Type 1~ Many 0/6 3.3 + 0.6 P < 0.1 PBS 0/6 2.2 +_ 0-2 1081 * Mice received an intraperitoneat injection of 0.1 ml of antiserum or ascitic fluid 2 h before challenge and of 0.1 ml of antibody 24 h after challenge. Mice were challenged by intracerebral inoculation with HSV-1 strain HFEM.
? Rabbit general antiserum to HSV-1 structural and non-structural polypepudes. ++ Probability levels for treatments that were significantly different from the PBS control which received no antibody. * Reciprocal of 50% endpoint dilution after incubation for 2 h at 26 °C with HSV-1 strain HFEM. 1" Groups of mice received either two (gB, gB + gC, pure HSV-1) or three (gC) footpad injections each containing about 10 gg of HSV-I strain HFEM antigen. Samples were taken from several mice, 5 days or 9 weeks after the final boost, and pooled.
++ ND, Not determined. Immunizing antigen* Survivors/total ° o Surviva Survivors total ° o Survival gC 6/6 100 5/5 100 gB 6/6 100 4/4 100 gB + gC 5/5 10(/ 2/2 100 Pure HSV-I 6/6 100 ND + ND PBS 0/4 0 2/6 33 * Mice received either two (gB + gC, pure HSV-I ) or three (gB, gC) footpad injections each containing about 10 ~tg of HSV-I strain HFEM antigen. t Mice were challenged by intracerebral inoculation, 5 days or 9 weeks after the final boost, with HSV-[ strain HFEM.
++ ND, Not determined
Passice immunization
Initial experiments were performed to determine whether the monoclonal antibodies would protect mice against a lethal dose of HSV-1. AIthough mouse death was not prevented, treatment with a mixture of the monoclonal antibodies to gB and gC or an HSV-1 general antiserum did produce small but significant increases in survival time (Table 3) .
Active immunization
Because passive immunization with the monoclonal antibodies had only proved partially effective, further work focused on using virus glycoproteins purified by immunoadsorption chromatography for active immunization. The levels of neutralizing antibody induced in mice by purified gC or a mixture of gB and its precursor pgB, purified using A7 or ~C3 respectively, was investigated. Both glycoproteins induced good antibody levels which only dropped slightly over a period of 9 weeks (Table 4) . Immunized mice were resistant to challenge with a lethal dose of HSV-1 given either 5 days or 9 weeks after the final boost of antigen (Table 5 ). The use of a mixture of both glycoproteins was not necessary for conferring immunity. p.L. ROBERTS AND OTHERS
DISCUSSION
In the present study we have prepared and characterized two monoclonal antibodies to HSV-1, designated A7 and c~C3, which react with gC and gB respectively but which do not neutralize virus infectivity. However, some of the other monoclonal antibodies to HSV glycoproteins, including gC and gB, that have also been described (Showalter et al., 1981 ; Rector et al., 1982; Balachandran et al., 1982a; Pereira et al., 1982; Palfreyman et al., 1983; Cranage et al., 1983) , are able to neutralize virus infectivity. The proteins recognized by A7 and c~C3 were identified using standard procedures such as immunoprecipitation and immunoadsorption chromatography. In addition, the transfer of infected cell polypeptides of various glycoprotein-deficient mutants to nitrocellulose and their subsequent detection by immunoperoxidase, and also the passive haemagglutination assay using red blood cells coated with various virus antigens, proved to be novel techniques for the identification of the virus glycoproteins to which the monoclonal antibodies were directed.
Monoclonal antibodies allow the type-common or type-specific nature of individual HSV glycoproteins to be investigated. A type-common site is recognized on gB by monoclonal antibody ctC3. However both type-common as well as type-specific monoclonal antibodies directed to this glycoprotein have been reported (Showalter et al., 1981; Rector et al., 1982; Balachandran et al., 1982a; Pereira et al., 1982) . The monoclonal antibodies to HSV-1 gC that have been described, including A7, have all been type-specific. However, the fact that an HSV-2 general antiserum will react with purified HSV-1 gC, i.e. the A7 antigen, would suggest that type-common sites do in fact exist (Table 1) . Indeed a type-common monoclonal antibody to HSV-2 gC has recently been reported (Zweig et al., 1983) . Surprisingly, the monoclonal antibody to gC which we have prepared, rather than simply being type-specific, was in fact strain-specific. The existence of strain-specific determinants involved in HSV neutralization has been noted in previous studies (Killington et al., 1978) . Monoclonal antibodies to HSV glycoproteins have been described which react with a wide range of HSV-1 isolates and only one or two HSV-2 isolates or, conversely, which react with a wide range of HSV-2 isolates and only one or two HSV-1 isolates (Pereira et al., 1982) . However no other monoclonal antibody that is apparently strain-specific has been described.
Monoclonal antibodies against HSV gB, gC, gD and gE including some that do not neutralize virus infectivity have been used to immunize mice passively and have resulted in protection levels against HSV-induced death ranging from 35 to 100 ~ (Dix et al., 1981 : Rector et al., 1982 Balachandran et al., 1982b; Sethi, 1983) . In our case, monoclonal antibodies to gC or gB showed no protective effect when used individually but when combined they produced a slight increase in mouse survival time after intracerebral virus challenge but did not prevent mouse death. Others have used less drastic routes when challenging with virus, i.e. eye or footpad inoculation, which may give the antibody a much greater opportunity to prevent the infection spreading to the central nervous system. In addition, one monoclonal antibody directed against a HSV-2 glycoprotein that does not protect mice against death has been reported (Balachandran et al., 1982b) .
Active immunization, using glycoproteins purified by immunoadsorption chromatography with the monoclonal antibodies A7 and ctC3, proved to be a more effective method for protecting mice against a lethal HSV-I infection. Purified gC or a mixture of gB and its precursor pgB induced good levels of neutralizing antibody and mice were completely protected against intracerebral challenge with a lethal dose of HSV. It has been suggested that the bloodbrain barrier delays IgG-mediated HSV clearance from the central nervous system (McKendall, 1983) . However, in our case the presence of this barrier did not prevent immunity being expressed. Virus neutralization may only be part of the immune mechanism involved in the protection obtained using purified gB or gC. The capacity of the cell-mediated immune response to confer adoptive immunity to HSV has also been demonstrated (Rager-Zisman & Allison, 1976; Howes et al., 1979; Nash et al., 1980; Sethi et al., 1983) .
The purification of a high mol.wt. HSV-1 glycoprotein from a Triton X-100 extract of infected cells using hydroxylapatite chromatography has been reported by Schrier et al. (1983) . Mice immunized with this antigen displayed type-specific hypersensitivity and protective immunity although no neutralizing antibody was found. The antigen was identified as gC from its apparent mol.wt, and its ability to react with an antiserum to HSV-1 but not HSV-2. In our studies the identity of gC has been more convincingly established by the use of glycoproteindeficient mutants. In contrast to the work of Schrier et al. (1983) , our purified HSV-I gC was found to react in a type-common fashion in passive haemagglutination tests and to induce neutralizing antibody in mice.
Our studies have shown that purified HSV gC or gB, purified by immunoadsorption chromatography, can be used to vaccinate mice against HSV. Recent work has shown that HSV gD is also effective (Long et al., 1984) . Thus each of several HSV glycoproteins can be considered as potential candidates for an HSV subunit vaccine. These provide alternatives to the use of membrane extracts from purified virus or infected cells (Wise et al., 1977; Skinner et al., 1980; Allen & Rapp, 1982; Cappel et al., 1982) . However, the ability of vaccination to prevent the establishment of latency needs to be investigated. Although infected cells provided reasonable yields of virus glycoproteins, it can be anticipated that genetically engineered microorganisms will prove a more cost-effective source. Indeed, the expression of immunologically active gD in Escherichia coli has recently been described (Weis et al., 1983) . However, from whatever source, specific HSV glycoproteins can be efficiently purified using immunoadsorption methods.
